Premium
Unprecedented Theranostic LaB 6 Nanocubes‐Mediated NIR‐IIb Photodynamic Therapy to Conquer Hypoxia‐Induced Chemoresistance
Author(s) -
Kuthala Naresh,
Vankayala Raviraj,
Chiang ChiShiun,
Hwang Kuo Chu
Publication year - 2020
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202002940
Subject(s) - photodynamic therapy , hypoxia (environmental) , cancer research , materials science , tumor hypoxia , doxorubicin , oxygen , reactive oxygen species , magnetic resonance imaging , nanotechnology , chemotherapy , medicine , radiation therapy , chemistry , biochemistry , radiology , organic chemistry
Tumor hypoxia and chemoresistance are long‐lasting challenges in clinical cancer treatments resulting in treatment failures and low patient survival rates. Application of phototherapies to treat deep tissue‐buried tumors has been hampered by the lack of near infrared photosensitizers, and consumption of tissue oxygen, worsening the tumor hypoxia problem. Herein, an unprecedented theranostic lanthanum hexaboride‐based nanodrug is engineered to act as bimodal computed tomographic/magnetic resonance imaging contrast agents, absorb long near infrared (NIR) light in the biological window IIb (1500–1700 nm), generate hydroxyl radicals without using oxygen, and destroy drug‐resistant NCI‐H23 lung tumors completely, leading to an amazingly long average half‐life of 180 days, far exceeding than those of doxorubicin‐treated (21 days) and untreated mice groups (13 days). This work pioneers the field of photodynamic therapy in conquering hypoxia and chemodrug resistance problems for NIR‐IIb oxygen‐independent cancer treatments.